398 results on '"Rustin, G. J."'
Search Results
2. Circulating Tumour Markers in Clinical Practice for the Early Detection of Cancer
3. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed
4. Clinical trials in ovarian carcinoma: study methodology
5. Re: Pathological Findings after Primary Chemotherapy in Patients Undergoing Simultaneous Orchidectomy and Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumours
6. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
7. Studies on alkaline phosphatase in neutrophils from controls, pregnant women, and patients with chronic granulocytic leukemia
8. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy
9. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
10. Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors
11. Primary retroperitoneal germ cell tumours: excision via a thoracoabdominal extraperitoneal approach
12. Teratomas Of The Ovary
13. Inhibin And Hydatidiform Mole
14. Don't Ignore A Positive Pregnancy Test
15. Potential Use of Retinoids in Cancer Prevention and Treatment
16. Treatment of small cell lung cancer by eight weeks chemotherapy
17. Electron microscopic cytochemical localization of nucleoside phosphatases in normal and chronic granulocytic leukaemic human neutrophils
18. The ultrastructural localization of human neutrophil alkaline phosphatase in normal individuals during pregnancy and in patients with chronic granulocytic leukaemia
19. Chemotherapy for Malignant Ovarian Germ Cell Tumours
20. Chemotherapy of Advanced Malignant Teratomas
21. Chemotherapy for ovarian cancer--a consensus statement on standard practice
22. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
23. Trial of Etretinate in Patients with Solid Tumours1
24. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
25. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours
26. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.
27. The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).
28. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
29. Assessing the value of weekly full blood counts (FBC) in patients with advanced serous gynecologic cancers receiving weekly carboplatin/paclitaxel (wCP) chemotherapy.
30. Novel strategy to identify drugs that delay relapse.
31. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
32. Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.
33. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
34. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
35. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
36. A phase I/II trial of radioimmunotherapy with 131Iodine labelled A5B7 anti-CEA antibody (131I-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas
37. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
38. Phase I evaluation of vascular disrupting agent OXi4503
39. Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
40. Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis
41. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
42. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours
43. SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
44. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
45. An assessment of mid-chemotherapy CT scanning as a predictor of a residual retroperitoneal mass in good prognosis metastatic teratoma of the testis
46. A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer
47. Use of changes in CA125 doubling time to detect activity of cytostatic agents in women relapsing with ovarian carcinoma. Study 1 - tamoxifen
48. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies
49. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
50. RESPONSE: Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.